Cytori's StemSource(R) Cell Bank to Be Installed at Leading Cosmetic & Reconstructive Surgery Network in Japan

San Diego, (PresseBox) - Cytori Therapeutics (NASDAQ: CYTX) received an order for a StemSource(R) Cell Bank from Cosmetic Surgery Seishin in Japan. The Cell Bank includes a StemSource(R) processing system along with all other equipment, software, database, and protocols required to cryopreserve patients' own adiposederived regenerative cells when the cells are younger and more viable.

"I have been using Cytori's products for over three years and they have become an integral part of my practice," said Dr. Tatsuro Kamakura, Chief Medical Officer of Cosmetic Surgery Seishin. "I have seen an increasing demand among my patients for the ability to bank their cells for their own future use. Having a StemSource(R) Cell Bank will further distinguish our growing practice."

The Cell Bank is expected to be installed during the next few months. Cosmetic Surgery Seishin, one of Cytori's existing customers, is one of the largest networks of cosmetic and reconstructive surgery centers in Japan. Cytori believes that cosmetic surgery centers are well suited as StemSource(R) Cell Bank customers, as these practices perform liposuction procedures on a regular basis.

The foundation of the cell bank is Cytori's StemSource(R) System, which automates the processing of regenerative cells from adipose tissue. This function facilitates the preparation and storage of the cells, thereby creating economic and process efficiencies that would otherwise make cell banking too expensive or time consuming.

Cautionary Statement Regarding Forward-Looking Statements

This communication includes forwardlooking statements regarding events, trends and business prospects, which may affect our future operating results and financial position. Such statements are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks include clinical and regulatory uncertainties, including risks in the collection and results of clinical data, final clinical outcomes, dependence on third party performance, and other risks and uncertainties described under the "Risk Factors" in Cytori's Securities and Exchange Commission Filings. We assume no responsibility to update or revise any forwardlooking statements to reflect events, trends or circumstances after the date they are made.

Cytori Therapeutics, Inc.

Cytori is an emerging leader in regenerative medicine, providing patients and physicians around the world with medical technologies that harness the potential of adult regenerative cells from adipose tissue. The Celution(R) System family of medical devices and instruments is being sold into the European and Asian cosmetic and reconstructive surgery markets but is not yet available in the United States. Our StemSource(R) product line is sold globally for cell banking and research applications. www.cytori.com

Press releases you might also be interested in

Subscribe for news

The subscribtion service of the PresseBox informs you about press information of a certain topic by your choice at a choosen time. Please enter your email address to receive the email with the press releases.

An error occurred!

Thank you! You will receive a confirmation email within a few minutes.


I want to subscribe to the gratis press mail and have read and accepted the conditions.